Literature DB >> 28125447

The microenvironment in primary cutaneous melanoma with associated spontaneous tumor regression: evaluation for T-regulatory cells and the presence of an immunosuppressive microenvironment.

Arielle Gray1, Solomiya Grushchak, Kumaran Mudaliar, Stephanie Kliethermes, Kyle Carey, Kelli A Hutchens.   

Abstract

Spontaneous tumor regression, regression in the absence of therapeutic intervention, can be identified histologically in over 25% of primary cutaneous melanomas at initial diagnosis. A unique subset of T lymphocytes found in areas of regression can be histologically distinguished from tumor-infiltrating T lymphocytes (TIL) found in areas of tumor progression. We call this unique subset of T lymphocytes regression-associated T lymphocytes (RATs). The aim of this study is to determine the phenotype of lymphocytes and the density of specific cell types linked to immunosuppression in areas of tumor progression compared with areas of tumor regression. These specific cell types include T-regulatory cells (Tregs) and S100A9 cells. A total of 14 primary cutaneous melanomas with areas of progression and regression were used. Immunohistochemistry staining was used to identify CD4 cells, CD8 cells, Tregs, and S100A9 cells. Two independent observers manually counted three high-powered ×40 fields. There was no predominance of CD4 or CD8 T lymphocytes in either RATs or TIL. We identified a lower density of Tregs in RATs compared with TIL when using the FOXP3/CD4 Treg marker (P=0.04) and a marginal difference when using our second, confirmatory Treg marker, FOXP3/CD25 (P=0.11). We observed a lower density of S100A9 cells in RATs compared with TIL (P=0.002). There was an observable difference in the tumor microenvironments of RATs and TIL, with RATs having a significantly lower density of Tregs and S100A9 cells. We deduce that the absence of immunosuppression in areas of regression allows for a more robust immune response and thus effective eradication of tumor cells.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28125447     DOI: 10.1097/CMR.0000000000000331

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  5 in total

1.  Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events.

Authors:  Cameron J Oswalt; Rami N Al-Rohil; Bala Theivanthiran; Tarek Haykal; April K S Salama; Nicholas C DeVito; Alisha Holtzhausen; Dennis C Ko; Brent A Hanks
Journal:  J Immunother       Date:  2022-05-30       Impact factor: 4.912

Review 2.  Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches.

Authors:  Ion G Motofei
Journal:  Curr Treat Options Oncol       Date:  2019-05-06

Review 3.  A long-term survivor with esophageal melanoma and pulmonary metastasis after single-stage esophagectomy and lobectomy: Case report and literature review.

Authors:  Tian Zhao; Feng-Wei Kong; Heng Wang; Dong Liu; Chun-Ying Wang; Jin-Hua Luo; Miao Zhang; Wen-Bin Wu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

4.  Chemical carcinogen safety testing: OECD expert group international consensus on the development of an integrated approach for the testing and assessment of chemical non-genotoxic carcinogens.

Authors:  Miriam N Jacobs; Annamaria Colacci; Raffaella Corvi; Monica Vaccari; M Cecilia Aguila; Marco Corvaro; Nathalie Delrue; Daniel Desaulniers; Norman Ertych; Abigail Jacobs; Mirjam Luijten; Federica Madia; Akiyoshi Nishikawa; Kumiko Ogawa; Kiyomi Ohmori; Martin Paparella; Anoop Kumar Sharma; Paule Vasseur
Journal:  Arch Toxicol       Date:  2020-06-27       Impact factor: 5.153

Review 5.  The role of tumour microenvironment: a new vision for cholangiocarcinoma.

Authors:  Ziyan Chen; Pengyi Guo; Xiaozai Xie; Haitao Yu; Yi Wang; Gang Chen
Journal:  J Cell Mol Med       Date:  2018-11-05       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.